glasgow-2997986_960_720

Scottish government invests £11m into Glasgow biotechnology centre

pharmafile | September 14, 2018 | News story | Medical Communications Biotechnology, IBioIC, Scotland, glasgow, scottish government 

The Scottish government is investing £11 million into the Glasgow-based Industrial Biotechnology Innovation Centre (IBioIC), an innovation centre which facilitates collaboration between the biotechnology industry and academia.

The investment is expected to help create an additional 500 new jobs and boost the Scottish economy as Brexit looms on the horizon. The IBioIC, which has more than 100 members which include a range of organisations from huge multinationals to small scale micro enterprises, is set to focus on developing leadership skills, accelerating commercialisation and enhancing the skills of Scotland’s biotechnology workforce.

Ivan McKee, Scotland’s Minister for Trade, Investment and Innovation commented that “Today’s investment from the Scottish Funding Council, Scottish Enterprise and Highlands and Islands Enterprise builds on the £120m already invested in Scotland’s eight innovation centres which are already having a transformational effect on our economy. I am pleased to confirm that the Scottish Government, through our national agencies, is able to invest £11.1m to support the IBioIC to drive forward Scotland’s industrial biotechnology sector.”

Dame Anne Glover, Chair of the IBioIC Governing Board, added that: “IB is an enabling technology, which underpins innovation in multiple sectors, and can contribute to reducing greenhouse gas emissions and the use of fossil fuels, as well as supporting sustainable production. IBioIC is, therefore, wonderfully positioned for a successful future in delivering significant value for the Scottish Government, businesses and general public.”

Louis Goss

Related Content

nhs_sign

NHS in Scotland makes rheumatoid arthritis drug available

The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for …

valneva-05

Valneva COVID-19 vaccine deal pulled by UK government

Boris Johnson and the UK government have terminated its deal with specialist vaccine company Valneva …

Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis

Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of …

Latest content